ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
ER
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.0field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 37 citations in OpenAlex.
- Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients.Breast cancer research : BCR · 2019Trial
- The effects of Palbociclib and Ferulic acid combination on cellular processes in breast cancer.Discover oncology · 2026Article
- Evaluation of targeted and immune combination therapies in a rat model of hormone receptor-positive breast cancer.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
- CDK1 Signaling in Cancer Treatment: Advances in AI-based Strategies and Tools for New Cancer Drug Discovery.Combinatorial chemistry & high throughput screening · 2026Article
- Review
- CDK4/6 Inhibitor Resistance in ER+ Breast Cancer.Advances in experimental medicine and biology · 2025Review
- Secondary Analysis of Human Bulk RNA-Seq Dataset Suggests Potential Mechanisms for Letrozole Resistance in Estrogen-Positive (ER+) Breast Cancer.Current issues in molecular biology · 2024Article
- Article
- The MonarchE trial: improving the clinical outcome in HRCancer communications (London, England) · 2023Article
- BAP18 facilitates CTCF-mediated chromatin accessible to regulate enhancer activity in breast cancer.Cell death and differentiation · 2023Article
- Prognostic and Predictive Value ofPharmaceutics · 2023Article
- Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy.NPJ precision oncology · 2023Article
- Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer.Cancers · 2022Article
- Article
- ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.Breast cancer research : BCR · 2021Review
- The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer.NPJ breast cancer · 2021Article
- Intrinsic and acquired resistance to CDK4/6 inhibitors and potential overcoming strategies.Acta pharmacologica Sinica · 2021Review
- Review
- Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer.Nature communications · 2020Article
Corrections and comments
- Erratum issuedCorrection: ER2019
Authors and funding
22 authors at 7 institutions in 3 countries.
Angel L Guerrero-ZotanoDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Thomas P StrickerPathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Luigi FormisanoDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Katherine E HutchinsonDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-4660-3523
Daniel G StoverDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Kyung-Min LeeDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Luis J SchwarzDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Jennifer M GiltnanePathology, Microbiology & Immunology, Vanderbilt University Medical Center, Nashville, Tennessee.
Monica V EstradaBreast Cancer Program, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-9846-8223
Valerie M JansenDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Alberto ServettoDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Joaquín GaviláDepartment of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
J Alejandro Perez-FidalgoDepartment of Oncology and Hematology, Hospital ClinicoUniversitario, INCLIVA Biomedical Research Institute, University of Valencia, CIBERONC, Valencia, Spain.
Ana LluchDepartment of Oncology and Hematology, Hospital ClinicoUniversitario, INCLIVA Biomedical Research Institute, University of Valencia, CIBERONC, Valencia, Spain.
Antonio Llombart-CussacDepartment of Medical Oncology, Hospital Arnau de Vilanova, Valencia, Spain.
Mohamed Amine BayarService de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.ORCID 0000-0002-9513-900X
Stefan MichielsService de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France.
Fabrice AndréDepartment of Medical Oncology, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.
Mónica ArnedosDepartment of Medical Oncology, Université Paris-Saclay, Gustave Roussy Cancer Campus, Villejuif, France.
Vicente GuillemDepartment of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
Amparo Ruiz-SimonDepartment of Medical Oncology, Instituto Valenciano de Oncología, Valencia, Spain.
Carlos L ArteagaDepartments of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. carlos.arteaga@utsouthwestern.edu.
Vanderbilt University Medical Center · USFundación Instituto Valenciano de Oncología · ESINCLIVA Health Research Institute · ESUniversité Paris-Saclay · FRUniversité Paris-Sud · FRDana-Farber Cancer Institute · USHospital Arnau de Vilanova · ES
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MTranslational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MUT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7MTISSUE CoreP50CA098131 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PARK, BEN HO, PIETENPOL, JENNIFER A · 2003 to 2024
$48.7MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MNCI NIH HHS K12 CA090625NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA068485NCI NIH HHS P30 CA142543NCI NIH HHS P50 CA098131
Abstract
PubMed holds no abstract for this paper.
Indexed as
Drug Resistance, NeoplasmAgedAged, 80 and overAromatase InhibitorsBiomarkers, TumorBreast NeoplasmsCell Line, TumorCell ProliferationComputational BiologyE2F4 Transcription FactorFemaleGene Expression ProfilingHumansLetrozoleMiddle AgedMutationAromatase InhibitorsBiomarkers, TumorE2F4 Transcription FactorLetrozoleProtein Kinase InhibitorsReceptors, Estrogen
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.